You are here

Short-Term Cost-Effectiveness of Bisphosphonate Therapies for Postmenopausal Osteoporotic Women at High Risk of Fracture

D. T. Grima, MSc, R. T. Burge, PhD, D. L. Becker, MSc, and A. N. A. Tosteson, ScD
PDF version: 
The authors evaluated the budget impact of risedronate and alendronate in the treatment of patients with postmenopausal osteoporosis.